Citations 2
Frequency and Clinical Outcomes Associated With Tau Positron Emission Tomography Positivity
Raghavan, Sheelakumari, Costoya‐Sánchez, Alejandro , Mainta, Ismini , Rodríguez-Fonseca, Omar Darío, Perissinotti, Andrés , Gu, Yuna , Yun, Jihwan, Peretti, Débora Elisa , Aguiar, Pablo , Bischof, Gérard N. , Seo, Sang Won , Villeneuve, Sylvia , O’Brien, John T. , Jagust, William, Frisoni, Giovanni B. , Soleimani‐Meigooni, David N. , Carrillo, Marı́a C., Joie, Renaud La , Rabinovici, Gil D. , Apostolova, Liana G. , Pontecorvo, Michael J. , Johnson, Keith A. , Weiner, Michael W. , Petersen, Ronald C., Jack, Clifford R. , Schöll, Michael , Labonté, Anne , Faubert, Anne‐Marie, Mathieu, Axel, Madjar, Cécile , Carrier, Charles Edouard, Kazazian, Christina, Lepage, Claude, Maillet, David , Michaud, Diane, Couture, Doris, Dea, Doris, Courcot, Blandine, Debacker, Clément , Fontaine, David, Knopman, David S. , Multhaup, Gerhard, Maltais, Jean‐Robert, Breitner, John C.S. , Poirier, Judes, Cheewakriengkrai, Laksanun, Sager, Mark A., Dauar‐Tedeschi, Marina, Rajah, Natasha, Aisen, Paul, Toussaint, Paule‐Joanne , Pierre, Bellec, Kostopoulos, Penelope, Étienne, Pierre , Tariot, Pierre N. , Orban, Pierre , Hoge, Rick, Thomas, Ronald J. , Gauthier, Serge , Craft, Suzanne , Montine, Thomas J. , Nair, Vasavan, Bohbot, Véronique D. , Venugopalan, Vinod, Ituria‐Medina, Yasser, Khachaturian, Zaven S., Teigner, Eduard, Anthal, Elena, Yu, Elsa, Ferdinand, Fabiola, Pogossova, Galina, Mayrand, Ginette, Duclair, Guerda, Gagné, Guylaine, Newbold‐Fox, Holly, Leppert, Illana, Tremblay‐Mercier, Jennifer , Frenette, Joanne, Frappier, Josée, Kat, Justin, Miron, Justin , Wan, Karen, Mahar, Laura, Carmo, Leopoldina, Théroux, Louise, Dufour, Marianne, Lafaille‐Magnan, Marie‐Élyse, Savard, Mélissa, Tuwaig, Miranda, Petkova, Mirela, Rioux, Pierre, Meyer, P.T., El‐Khoury, Rana, Gordon, Renee, Giles, Renuka, Das, Samir, Wang, Seqian, Tabrizi, Shirin , Mathotaarachchi, Sulantha , Dubuc, Sylvie, Lee, Tanya , Beaudry, Thomas, Gervais, Valérie, Pagé, Véronique, Desautels, René, Benbouhoud, Fatiha, Saint‐Fort, Eunice Farah, Verfaillie, Sander C.J. , Farzin, Sarah , Salaciak, Alyssa , Tullo, Stéphanie , Daoust, Leslie‐Ann, Köbe, Theresa , McSweeney, Melissa, Nilsson, Nathalie , Pishnamazi, Morteza, Bedetti, Christophe , Hudon, Louise, Greco, Claudia, Chapleau, Marianne , St‐Onge, Frédéric , Boutin, Sophie , Geddes, Maiya R. , Ducharme, Simon , Jean, Gabriel, Sylvain, Elisabeth, Élie, Marie‐Josee, Leblond‐Baccichet, Gloria, Soucy, Jean‐Paul , Ozlen, Hazal , Bailly, Julie, Mohammediyan, Béry, Chen, Yalin , Remz, Jordana, Rentz, Dorene M., Amariglio, Rebecca E. , Blacker, Deborah , Chhatwal, Jasmeer P. , Dickerson, Brad C., Donovan, Nancy J. , Farrell, Michelle E. , Gómez, Cristina Lois, Marshall, Gad A. , Oaoo, Kate, Price, Julie, Prokopiou, Prokopis C. , Reynolds, Gretchen , Skylar-Scott, Irina A., Vila‐Castelar, Clara , Yang, Hyun‐Sik , Trojanowki, John Q., Green, Robert C, Perrin, Richard J. , Shaw, Leslie M. , Potter, William Z. , Bernard, Marie , Jackson, Jonathan, Masliah, Eliezer , Masterman, Donna, Okonkwo, Ozioma, Ryan, Laurie, Silverberg, Nina, Fleisher, Adam , Fockler, Juliet , Conti, Cat, Jin, Chengshi , Nosheny, Rachel L. , Ashford, Mariam, Flenniken, Derek , Kormos, Adrienne, Montine, Tom, Rafii, Michael, Raman, Rema , Gessert, Devon, Salazar, Jennifer, Zimmerman, Caileigh, Cabrera, Yuliana, Walter, Sarah , Miller, Garrett, Coker, Godfrey, Clanton, Taylor, Hergesheimer, Lindsey, Smith, Stephanie , Adegoke, Olusegun, Mahboubi, Payam, Moore, Shelley, Pizzola, Jeremy, Shaffer, Elizabeth , Harvey, Danielle, Forghanian-Arani, Arvin, Borowski, Bret, Ward, Chad, Gunter, Jeff, Kantarci, Kejal, Thompson, Paul , Jahanshad, Neda , DeCarli, Charles , Knaack, Alexander , Fletcher, Evan, Chen, Stephanie R, Choe, Mark, Crawford, Karen , Yuschkevich, Paul A, Reiman, Eric M. , Mathis, Chet, Landau, Susan , Cairns, Nigel J. , Householder, Erin, Franklin, Erin , Bernhardt, Haley, Taylor‐Reinwald, Lisa, Korecka, Magdalena , Figurski, Michal, Neu, Scott, Nho, Kwangsik, Foroud, Tatiana M., Faber, Kelley , Wilmes, Kristi, Thal, Leon J., Dage, Jeffrey L. , Eloyan, Ani , Hammers, Dustin B. , Kirby, Kala, Kramer, Joel, Legarde, Julien, Murray, Melissa E., Newell, Kathy L. , Taurone, Alexander, Thangarajah, Maryanne, Touroutoglou, Alexandra , Clark, David , Day, Gregory S, Duara, Ranjan , Graff-Radford, Neill R, Grant, Ian , Masdeu, Joseph C. , Mendez, Mario F. , Onyike, Chiadi U. , Riddle, Meghan , Rogalskı, Emily , Salloway, Steven, Sha, Sharon J. , Carrillo, María C. , O'Brien, John Tiernan , Jack, Clifford R , Schöll, Michael , La Joie, Renaud , Rabinovici, Gil D , Dage, Jeffrey L , Rial, Alexis Moscoso , Heeman, Fiona , Raghavan, Sheelakumari , Essen, Martijn van , Camacho, Valle , Silva‐Rodríguez, Jesús , Ribaldi, Federica , Coomans, Emma M. , Brum, Wagner Scheeren , Grothe, Michel J. , Drzezga, Alexander E. , Malpetti, Maura , Rowe, James B. , Giessen, Elsmarieke van de , Ossenkoppele, Rik , Smith, Ruben , Hansson, Oskar , Garibotto, Valentina , Dickerson, Bradford Clark , LaMontagne, Pamela , Sperling, Reisa Anne , Vemuri, Prashanthi , Tam, Angela , Binette, Alexa Pichet , Dansereau, Christian , Picard, Cynthia , Michaud, Diane, Couture, Doris, Cuello, A. Claudio , Barkun, Alan , Evans, Alan Charles , Tardif, Christine Lucas , Knopman, David S. , Near, Jamie , Leoutsakos, Jeannie‐Marie , Brandt, Jason , Pruessner, Jens C. , Morris, John C. , Collins, D. Louis , Chakravarty, M. Mallar , Eisenberg, Mark Jeffrey , Rajah, Maria Natasha , Rosa-Neto, Pedro , Bellec, Pierre , Thomas, Ronald, Fonov, Vladimir , Vallee, Isabelle, Vogel, Jacob W. , Dadar, Mahsa , Appleby, Melissa , Meyer, Pierre‐François, Gonneaud, Julie , Pascoal, Tharick Ali , Vachon‐Presseau, Étienne , Spreng, R. Nathan , Rentz, Dorene M. , Buckley, Rachel F. , Gagliardi, Geoffroy Pierre , Gatchel, Jennifer R. , Guzmán‐Vélez, Edmarie , Jacobs, Heidi I.L. , Jutten, Roos J. , Pardilla‐Delgado, Enmanuelle , Price, Julie C. , Quiroz, Yakeel T. , Schultz, Aaron P. , Schultz, Stephanie A. , Sepulcre, Jorge , Vannini, Patrizia , Toga, Arthur W. , Beckett, Laurel , Saykin, Andrew J. , Potter, William, Barnes, Lisa L. , Gonzalez, Hector, Ho, Carole , Hsiao, John , Jackson, Jonathan , Veitch, Dallas P. , Neuhaus, John M , Rafii, Michael S. , Jimenez‐Maggiora, Gustavo Adolfo , Donohue, Michael , Arani, Arvin , Schwarz, Christopher G. , Jones, David T. , Kantarci, Kejal , Senjem, Matthew L. , Reid, Robert I. , Fox, Nick C. , Malone, Ian B. , Thomopoulos, Sophia I. , Nir, Talia M. , Tosun, Duygu , Das, Sandhitsu R. , Koeppe, Robert A. , Chen, Kewei , Risacher, Shannon L. , Shen, Li , Nudelman, Kelly , Ghetti, Bernardino , Grinberg, Lea T. , Hammers, Dustin B , Kirby, Kala, Kukull, Walter A. , Murray, Melissa E. , Polsinelli, Angelina J. , Atri, Alireza , Duara, Ranjan , Graff‐Radford, Neill R. , Honig, Lawrence S. , Johnson, Erik C. B. , Masdeu, Joseph C , Musiek, Erik , Salloway, Steve , Turner, Raymond Scott , Wingo, Thomas S , Wolk, S. J. , Womack, Kyle
JAMA | June 16, 2025 | Volume: 334 | Issue: 3 | Pages: 229
Importance Tau positron emission tomography (PET) allows in vivo detection of neurofibrillary tangles, a core neuropathologic feature of Alzheimer disease (AD). Objective To provide estimates of the frequency of tau PET positivity and its associated risk of clinical outcomes. Design, Setting, and Participants Longitudinal study using data pooled from 21 cohorts, comprising a convenience sample of 6514 participants from 13 countries, collected between January 2013 and June 2024. Cognitively unimpaired individuals and patients with a clinical diagnosis of mild cognitive impairment (MCI), AD dementia, or other neurodegenerative disorders were included. Exposures Tau PET with flortaucipir F 18, amyloid-β (Aβ) PET, and clinical examinations. Tau PET scans were visually rated as positive according to a US Food and Drug Administration– and European Medicines Agency–approved method, designed to indicate the presence of advanced neurofibrillary tangle pathology (Braak stages V-VI). Main Outcomes and Measures Frequency of tau PET positivity and absolute risk of clinical progression (eg, progression to MCI or dementia). Results Among the 6514 participants (mean age, 69.5 years; 50.5% female), median follow-up time ranged from 1.5 to 4.0 years. Of 3487 cognitively unimpaired participants, 349 (9.8%) were tau PET positive; the estimated frequency of tau PET positivity was less than 1% in those aged younger than 50 years, and increased from 3% (95% CI, 2%-4%) at 60 years to 19% (95% CI, 16%-24%) at 90 years. Tau PET positivity frequency estimates increased across MCI and AD dementia clinical diagnoses (43% [95% CI, 41%-46%] and 79% [95% CI, 77%-82%] at 75 years, respectively). Most tau PET–positive individuals (92%) were also Aβ PET positive. Cognitively unimpaired participants who were positive for both Aβ PET and tau PET had a higher absolute risk of progression to MCI or dementia over the following 5 years (57% [95% CI, 45%-71%]) compared with both Aβ PET–positive/tau PET–negative (17% [95% CI, 13%-22%]) and Aβ PET–negative/tau PET–negative (6% [95% CI, 5%-8%]) individuals. Among participants with MCI at the time of the tau PET scan, an Aβ PET–positive/tau PET–positive profile was associated with a 5-year absolute risk of progression to dementia of 70% (95% CI, 59%-81%). Conclusions and Relevance In a large convenience sample, a positive tau PET scan occurred at a nonnegligible rate among cognitively unimpaired individuals, and the combination of Aβ PET positivity and tau PET positivity was associated with a high risk of clinical progression in both preclinical and symptomatic stages of AD. These findings underscore the potential of tau PET as a biomarker for staging AD pathology.
Benefits and risks of FDA‐approved amyloid‐targeting antibodies for treatment of early Alzheimer's disease: Navigating clinician‐patient engagement
Rentz, Dorene M., Aisen, Paul, Hitchcock, Janice M., Irizarry, Michael C. , Landen, Jaren W., Matthews, Brandy R., Miller, David S. , Napoli, Salvatore , Okhravi, Hamid , Petersen, Ronald C., Siemers, Eric , Weber, Christopher J., Weisman, David C., Carrillo, María C. , Rentz, Dorene M. , Atri, Alireza , Miller, David S., Mahinrad, Simin , Napoli, Salvatore, Petersen, Ronald C.
Alzheimer's & Dementia | September 22, 2024 | Volume: 20 | Issue: 11 | Pages: 8162-8171
AbstractThe emergence of the United States Food and Drug Administration (FDA)‐approved amyloid‐targeting therapies for Alzheimer's disease challenges clinicians and healthcare providers with a transformative landscape. Effectively communicating the risks, benefits, burdens, costs, and available support associated with these novel disease‐modifying treatments to patients, families, and other healthcare providers is essential but complex. In response, the Alzheimer's Association's Clinical Meaningfulness Workgroup has proposed language surrounding treatment eligibility, benefits, amyloid‐related imaging abnormalities (ARIA), apolipoprotein E (APOE) genotyping, and treatment costs, serving as a resource to healthcare professionals in navigating discussions with patients and their families. As the landscape evolves with the approval of new Alzheimer's therapies, this resource stands poised for updates, ensuring its continued relevance in facilitating informed and meaningful patient‐provider dialogues.Highlights Effective communication of risks, benefits, burdens, and costs of FDA‐approved amyloid‐targeting antibodies is essential to patients, families, and healthcare providers. The Alzheimer's Association's Clinical Meaningfulness Workgroup provides language for physicians and healthcare providers around treatment eligibility, benefits, ARIA, APOE genotyping, and treatment costs. This supplementary resource may be updated as new AD therapies become approved.